Drugs / Virus Specific T cells (VSTs)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03180216 | Feb 2017 → Mar 2026 overdue | disease related to hematopoietic stem cell transplant, viral infectious disease | Children's National Research Institute | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Virus Specific T cells (VSTs) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03180216 ↗ |
| Action | Restore | “cellular immunotherapy to restore viral-specific immunity” NCT03180216 ↗ |
| Modality | Cell therapy | “rapidly generated multivirus-specific T-cell products” NCT03180216 ↗ |